skip to Main Content

Early stage breast cancer test based on blockchain

1 token = 0,00026 ETH

10 tokens = 1 Breast Cancer Test

1 BC test = 100 – 500$ (dépend du pays)


Pré-vente terminée avec succès!

Jeton total émis: 883.323 $!

La vente de jetons ARNA a commencé
Adhérer!

1 (1)
ARNA Panacea ICO rating
награда

The utility function of ARNA token is available now

You can change 10 ARNA tokens to 1 ARNA BC test.
ARNA BC waitlist will open December 21,  2017
Get waitlisted now to make sure you are in front of millions.

Votre chance d’entrer sur le marché de la biotechnologie

ARNA Genomics est une société biotechnologique innovante engagée dans la R&D et le lancement sur le marché des méthodes de détection précoce des maladies oncologiques en utilisant l’écosystème de la blockchain ARNA Panacea.

overview

ARNA BC est le premier produit de test développé pour la détection précoce du cancer du sein avec une haute précision.

Qu’est-ce que ARNA

Le conseiller d’ARNA, Dmitry Kulish, parle du projet et de la blockchain d’ARNA. Entrevue complète

ARNA Genomics Intro

Présentation de ARNA Panacea

ARNA Panacea est une solution biotechnologique décentralisée, propulsée par la Blockchain et les jetons d’ARNA.

ARNA Panacea by design est une plateforme qui permet non seulement le traitement des données d’essais cliniques, mais aussi le soutien aux chercheurs pendant la phase de R&D et de commercialisation pour tous les types d’acteurs du marché impliqués dans les essais cliniques ainsi que la vente directe de produits biotechnologiques finaux aux clients (patients).

Précision
Mai 2018
96.04%
True: 97 False: 4
laptop

Cas d’utilisation d’ARNA Panacea

Preuve De Recherché

Preuve de recherché

Les données stockées dans la blockchain publique ARNA Panacea seront la base de la base de données probantes.

Recherche Protégée

Recherche protégée

La capacité de  “recherche scientifique”  dans un format sécurisé utilisant la clé cryptée dans l’écosystème de la blockchain.

Big Data

Big Data

Accès global à l’ensemble des informations accumulées via une interface API ouverte avec la fonctionnalité nécessaire à l’analyse des données disponibles.

Écosystème

Écosystème

Une seule plateforme de blockchain unique pour la collecte, le stockage et l’analyse des méthodes d’information pour le diagnostic et le traitement du cancer

Smart Blockchain

Smart Blockchain

La possibilité de connecter une IA à la recherche de  «patterns» pour développer de nouvelles méthodes de traitement du cancer

Jetons ARNA

Jetons ARNA

Utilisation par intéraction au sein de l’écosystème des patients, des chercheurs, du régulateur, du CRO, des sociétés pharmaceutiques, des cliniques.

Notre Marché est énorme

0B
femmes à l’échelle mondiale
0s
Des milliers de chercheurs en biotechnologie
0M
Tests ARNA BC seulement aux États-Unis et en Russie
0$B+
Fusions et acquisitions sur le marché médical au cours de chacune des 3 dernières années

ARNA Panacea Écosystème de Blockchain

rôles communautaires

  • 01 Registrateurs
  • 02 Des chercheurs
  • 03 Les compagnies d'assurance
  • 04 Compagnies pharmaceutiques
  • 05 Organismes de recherche sous contrat (CRO)
  • 06 Sponsors / Investisseurs
  • 07 Comités nationaux d'éthique
  • 08 MDs
  • 09 Cliniques
  • 10 Experts
  • 11 Régulateurs
  • 12 Big Data
  • 13 Les patients
  • 14 Statistiques

NOTRE VISION

Révolutionner la façon dont les technologies biotechnologiques perturbatrices visant à lutter contre le cancer sont lancées sur le marché de masse avec l’utilisation des technologies Blockchain

Équipe

Egor Melnikov

Egor Melnikov

Founder, CEO

More than 10 years ago started the project with mission to save lives from cancer. Economist and manager by education, entrepreneur by experience and spirit. Made several successful startups as founder and co-founder in advertising and production business, international logistics, IT solutions for large-scale projects, was CEO of international telecom operator. ARNA – is the meaning of Egor’s life.

George Nikitin

George Nikitin

Co-founder and COO, blockchain platform ideologist

Master of physics (diploma with honors), have 14 articles and inventions. Successfully worked in large international companies (Delloite, etc.), as well as in private equity companies. He has extensive experience as executive manager in various major private and public companies in IT, telecom, oil&gas.

Anatoliy Melnikov

Anatoliy Melnikov

Co-founder and HEAD of R&D, creator of ARNA tests

Having more than 40 years of experience in molecular biology and genetics, he is the author and co-author of more than 50 scientific articles and number of patents. For 15 years he worked in the USA in oncological centers, before that – in Canada, Hungary in various scientific companies, and Russia – a branch of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences and the Institute of Biochemistry and Physiology of Microorganisms of the Russian Academy of Sciences. He graduated from the biological faculty of the Lomonosov Moscow State University.

Ilya Senechkin

Ilya Senechkin

PhD in Life Sciences, Embryology Director ("Center IVF" network of clinics, Russia)

Development Manager for Scientific and Educational Programs (F. Paulsen Assisted Reproductive Technologies Center, Russian Ministry of Health). Former: medical advisor (MC Femina, Vitrolife), clinical embryologist (MD Medical Group), Jr. scientist (Wageningen University, The Netherlands)

Magomed Chatuev

Magomed Chatuev

Software architect and developer

CTO. Has a big experience working with start-ups in the areas of e-commerce, PR & Marketing, finance, transportation, ERP development. Mainly focused on building SaaS, APIs & complex business processes automation. Had been working in international companies in Russia, Ireland, and Germany.

Alexander Mazaletskiy

Alexander Mazaletskiy

Software Architect

Founder, CEO and Principal engineer in blockchain integrator Dicoiner (www.dicoiner.com) Founder and CEO in mobile development studio Zero Cool Team. 10 years experience in enterprise fintech software design and development. Last two yeast making research and implementation of blockchain systems. Graduate of IIDF-2015(Internet Initiatives Development Fund) in the team of Teslawatch startup.
15 scientific publications in the field of natural language processing

Sergey Dolgachev

Sergey Dolgachev

Co-founder, head of finance and risks management

Entrepreneur and co-owner of several companies in the oilfield service, medicine and biotech. He graduated from the Faculty of Computational Mathematics and Cybernetics of the Moscow State University Lomonosov, EMBA Higher School of Economics, studied at the Skolkovo Management School, INSEAD and graduate school of MGIMO. He has extensive executive experience in oil&gas public and private companies.

Vladimir Savanovich

Vladimir Savanovich

Co-founder, Head of Investor Relations

has a master’s degree in physics. During his professional experience, he worked in various business areas, mainly focusing on the active development of the contractual base of enterprises. He has experience in working in a Western consulting company, a resort development company, a Swiss investment fund and a Russian exploration company.

Consultants

Linda S. Pellicore

Linda S. Pellicore

Linda S. Pellicore graduated from Thomas Jefferson Medical College of Graduate Studies, Philadelphia, PA, with Ph.D.s in both Pharmacology and Toxicology, in 1987. She has 28 years expertise in New Drug Applications, Biologics, 510Ks, Food Additives and Dietary Supplements with the U.S. Food and Drug Administration, serving as the agency’s Senior Pharmacologist. She is a National Research Council Fellow, and is a member of numerous professional scientific societies.

Wesley Hymer, Ph.D

Wesley Hymer, Ph.D

Dr. Hymer is an Emeritus Professor of Biochemistry at Penn State and winner of Penn State’s Faculty Scholar Medal for Life and Medical Sciences. He has countless academic papers, grants and including several patents that were developed when he was Director of Penn State’s Center for Cell Research, and one patent related to medical devices enabling targeted chemotherapy for cancers treatments. He collaborated with NASA on biotechnology and biomedical experiments in microgravity and developed unique electrophoresis experiments executed on board the U.S. Space Shuttle and microsatellites.

Dmitry Kulish

Dmitry Kulish

Dmitry Kulish is an independent expert in the fields of strategic, organizational and technological development of pharmaceutical products. Dmitry holds a PhD in Biology, has been a postdoc at Harvard Medical School, earned MBA from the Wharton Business School, the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Moscow State Institute of Molecular Biology Lomonosov Moscow State University.

Dmitry Grigoriev

Dmitry Grigoriev

Over 20 years of successful general management experience with a particular focus on business development and operational excellence. Сonstant over 5 years trend in business development and financial results improvement for large European integrated company with over 8 bln. USD in turnover and presence in over 15 countries. Has implemented several very successful business alliances strategies where the managed companies/clients have benefited from new distribution channels/partners reach.

Ph.D DR. Soenke Bartling

Ph.D DR. Soenke Bartling

Ph.D DR. MED, Board certified Radiologist, blockchain for research & healthcare / Open Science. Sönke has a tremendous background in neuroradiology at Hannover Medical School, Institute for Radiology and Interventional Therapy and other sound scientific organizations. Apart from that Sönke is well-known due to his activity in Web 2.0 for science in 00x, following by working on Blockchain for Science and Open Science (awarded in 2015, Germany land of ideas) concepts. He is author of more than 20 scientific publications, number of reviews, books and 6 patents. Holds various awards and is a member of governmental groups on radiology and tomography.
Mikhail Groubman

Mikhail Groubman

Mikhail joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.

Marina Sekacheva

Marina Sekacheva

is a Doctor of Medical Sciences, a laureate of the Russian Government Prize in Science, a holder of post-doctoral degree in medicine of the Technical University of Munich, the Director of the Center for Personalized Oncology Sechenov OncoTarget, established as part of the Institute of Personalized Medicine in 2017

Ilya N. Chistyakov

Ilya N. Chistyakov

MD., PhD, founder and CEO of the Preclinical Study Centre LLC, managing company of “Pharma Valley” biotechnological cluster – the only GLP OECD in Russia, an independent hybrid CRO specialized on conducting a full cycle of pharmacological development, manufacturing, preclinical and clinical studies of biotechnological, biosimilar and generic medicines.

Ed Kanalosh

Ed Kanalosh

has more than 20 years of experience in biotech investments and strategic consulting. Partner of venture fund “Maxwell Biotech” (Moscow), director of consulting company Candesic (London). Edward is an acting head of Investment Service of Skolkovo fund, vice-president of Investment Bank “Trust” and consultant of New Jersey office of McKinsey company. His career has started in Bill and Melinda Gates Foundation Fund. MBA from Harvard Business School, MD with PhD.

Alex Kosik

Alex Kosik

Dr. Alex Kоsik is a successful serial technology entrepreneur. His focus is in Life Sciences, Medical Devices, FDA Compliance, Evidence-Based Medicine, Venture Capital and M&A. Alex is a recognized technology due diligence expert and senior analyst to several VC’s, angels, Gerson Lehrman Group and institutional investors. He co-founded multiple businesses himself, met Bill Gates, sold his “G1 Gravitonus workstations” to Forbes-100, and ranked 3rd by Becker’s Spine Review of “10 spine orthopedic surgeon tech entrepreneurs to know”

Sergey Borovskiy

Sergey Borovskiy

worked and lived in China since 1991. He has more than 20 years of experience in international management in China and Hong Kong. He held the positions of Chairman of the Board of Directors in various companies in China involved in international trade, investment and production. Since 2017, he was the General Manager of Sanju Environmental Protection (Hong Kong) Limited, coordinating the international projects of the controlling shareholder.

Quelle est la fonctionnalité du jeton?

B2 Dir

JANET WOODCOCK – (Directeur du Centre d’évaluation des médicaments et de recherche à la Food and Drug Administration)

“Personnellement, je crois, comme beaucoup d’autres personnes, que le système d’essais cliniques que nous avons actuellement est brisé. Il ne fonctionne pas pour atteindre les objectifs dont nous avons besoin pour”

  • 10 jetons de la vente principale (0.03333 ETH) peuvent être utilisés pour acheter 1 test ARNA BC. Le prix moyen prévu du marché pour un test ARNA BC est de 0.3333 ETH.
  • Les détenteurs d’un grand nombre de jetons pourront participer au programme de récompenses VIP de l’ARNA, offrant ainsi une occasion sans précédent.
  • Les jetons ARNA seront utilisés sur la plate- forme ARNA Panacea comme monnaie de cryptage pour les paiements entre les participants à la plate forme.
  • Les chercheurs pourront organiser des événements de crowdfunding » sur leurs inventions révolutionnaires en biotechnologie.
  • … et autres utilisations – en savoir plus dans notre Livre blanc.

Jetons and Fonds

ARNA at conferences

[big-v2]conference2

Moscow

International blockchain forum

[big-v2]conference3

Monaco 

MGF Holiday Blockchain Edition CryptoBazar Exclusive

[big-v2]conference1

New York

Blockchain economic forum 2017

[big-v2]conference5

Hong Kong

The 30th Annual AVCJ Private Equity & Venture Forum

[big-v2]conference6

Los Angeles

World funding summit & capital expo

[big-v2]conference4

Santa Clara

Blockchain in the healthcare system

Documents

One Pager

ARNA market overview

Whitepaper

whitepaper

Market Overview

Market Overview

Roadmap

2013 2019
[carousel_anything]

2013

ARNA Genomics a été établie
Obtention du statut de membre du pôle biomédical Skolkovo

2014

Cycle de semences; Développement de l’ARNA-Thermometr, test de détection de la présence de maladies oncologiques; formalisation des objets “Savoir-faire”.

2015

Développement de ARNA Breast Cancer – un test de haute précision pour la détection précoce du cancer du sein

2016

Développement de ARNA Colon Cancer;
Le développement de l’ARNA BC est terminé.
Début des tests de laboratoire d’ARNA BC; Dépôt de la demande de brevet no 1

2017

Fin des tests de laboratoire d’ARNA BC; Début de la recherche clinique d’ARNA BC en collaboration avec l’Université Sechenov; Soumission de la demande d’application du Traité de coopération en matière de brevets n°1; Événement de distribution de jetons

2018

Ouverture du bureau et de la 1ère unité de laboratoire aux USA. Soumission de la demande d’application du traité de coopération en matière de brevets n° 2 et 3. Entente sur la stratégie de réglementation d’ARNA BC. Lancement de la recherche clinique N°1 aux Etats-Unis avec la FDA. L’élaboration de ARNA CC est terminée et la recherche en laboratoire commence. ARNA Panacea – lancement de la version bêta de l’écosystème blockchain, documentation de base pour les développeurs

2019

Utilisation de l’écosystème de la blockchain d’ARNA Panacea par les acteurs intéressés du marché (régulateurs, investisseurs, utilisateurs, etc.) Début du développement: ARNA Lung, ARNA Liver, ARNA Pancreas; l’entrée d’ARNA BC sur le marché américain; Essais cliniques en Chine; Phases nationales: USA, Chine, Inde, UE, Royaume-Uni, Israël, Brésil; Cycle de semences B; Recevoir les premières recettes.

[/carousel_anything]

Partienaires

Médias

logo-300×77
steemit
NewsBTC-Logo
logo-home-new
forclog
coin-min
logo
Безымянный
tokenmarket
coingecko-logo
cryptocoinsnews-vector-kopi-1-1
smith+crown
3423420
1.Bitcoininsider
2.Themerkle
3. THE COINTELEGRAPH 11
4.Huffpost
5.NEWS